(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Picking Your Next SUV: 4 Brands Offering Execution, Solace, and Wellbeing - 2Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- 3Are IDF reservists properly armed during post-war operations?
- 4The secret appeal of Harlan Coben’s messy, addictive TV thrillers
- 5Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- New portrait of the oldest-known supernova | Space photo of the day for March 27, 2026
- 6 Agreeable Earphones To Wear
- Bayer sues COVID vaccine makers over mRNA technology
- Sahel coups push Africa to top of global democratic declines, report finds
- 21 Incredibly Entertaining Contemplations To Observe Consistently
- Saudi Arabia says it intercepted 7 missiles, debris falls near energy facilities
- 6 Exemplary Mexican Dishes
- Step by step instructions to Prepare with Senior Protection for Inward feeling of harmony.
- Extreme Manual for Picking a Camper Van
